Cargando…
Gene dysregulation is restored in the Parkinson’s disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm)
The administration of MPTP selectively targets the dopaminergic system resulting in Parkinsonism-like symptoms and is commonly used as a mice model of Parkinson’s disease. We previously demonstrated that the neuroprotective compound Cu(II)(atsm) rescues nigral cell loss and improves dopamine metabol...
Autores principales: | Cheng, Lesley, Quek, Camelia Y. J., Hung, Lin W., Sharples, Robyn A., Sherratt, Nicki A., Barnham, Kevin J., Hill, Andrew F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772163/ https://www.ncbi.nlm.nih.gov/pubmed/26928495 http://dx.doi.org/10.1038/srep22398 |
Ejemplares similares
-
Restoration of intestinal function in an MPTP model of Parkinson’s Disease
por: Ellett, L. J., et al.
Publicado: (2016) -
The hypoxia imaging agent Cu(II)(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease
por: Hung, Lin W., et al.
Publicado: (2012) -
Cu(II)(atsm) Attenuates Neuroinflammation
por: Choo, Xin Yi, et al.
Publicado: (2018) -
(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012) -
Cellular Uptake of the ATSM−Cu(II) Complex under Hypoxic Conditions
por: Walke, Gulshan R., et al.
Publicado: (2021)